Fig. 10: Solanesol mitigates LPC-induced ERK activation, ameliorates cognitive and motor deficits in LPC-induced mice. Additionally, it restores physiological lysosomal acidity and enhances the survival of dopaminergic neurons. | npj Parkinson's Disease

Fig. 10: Solanesol mitigates LPC-induced ERK activation, ameliorates cognitive and motor deficits in LPC-induced mice. Additionally, it restores physiological lysosomal acidity and enhances the survival of dopaminergic neurons.

From: Lysophosphatidylcholine promoting α-Synuclein aggregation in Parkinson’s disease: disrupting GCase glycosylation and lysosomal α-Synuclein degradation

Fig. 10

a Schematic illustrating the process of drug injection and behavioral phenotype testing in mice. b, c Time spent in new arm in the Y- maze (n = 6, Control vs LPC: p < 0.0001, LPC vs LPC+Solanesol: p = 0.0001). d–g WB analysis of individual molecular weight α-Syn expression levels post-LPC and Solanesol interventions (n = 3, oligomers: Control vs LPC: p = 0.0061, LPC vs LPC + Solanesol: p = 0.0026; monomer: Control vs LPC: p = 0.0002, LPC vs LPC + Solanesol: p = 0.0004; oligomers/ monomer: Control vs LPC: p = 0.001, LPC vs LPC+Solanesol: p = 0.0098). h–k Expression levels of p-ERK, GRASP65, and Cleaved-Caspase3 analyzed by WB assay (n = 3, p-ERK: Control vs LPC: p < 0.0001, LPC vs LPC+Solanesol: p < 0.0001; GRASP65: Control vs LPC: p = 0.0002, LPC vs LPC+Solanesol: p = 0.0362; Cleaved-Caspase3: Control vs LPC: p = 0.0007, LPC vs LPC+Solanesol: p = 0.0006). l Flow cytometry analysis of apoptosis in MES23.5 dopaminergic neurons following LPC and Solanesol treatments. m Statistical analysis of the percentage of apoptotic cells (Q2 + Q3) (n = 3, Control vs LPC: p = 0.0005, LPC vs LPC+Solanesol: p = 0.0068). n, o Immunofluorescence co-labeling of LAMP1 and OG488.

Back to article page